449 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
SNY Sanofi $43.75 $109.14B N/A
Article Searches
Was ASCO Quieter for Big Drug/Biotech Stocks This Year? http://www.zacks.com/stock/news/425444/was-asco-quieter-for-big-drug-biotech-stocks-this-year?cid=CS-ZC-FT-425444 Jun 06, 2019 - The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options http://www.zacks.com/stock/news/424909/glaxos-nucala-gets-chmp-nod-for-2-self-administered-options?cid=CS-ZC-FT-424909 Jun 05, 2019 - GlaxoSmithKline (GSK) announces that the EMA???s Committee for Medicinal Products for Human Use has issued a positive opinion for two self-administered options of its asthma drug, Nucala.
Emergent (EBS) Wins HHS Contract to Supply VIGIV Product http://www.zacks.com/stock/news/424736/emergent-ebs-wins-hhs-contract-to-supply-vigiv-product?cid=CS-ZC-FT-424736 Jun 04, 2019 - Shares of Emergent (EBS) rise after the company gets a 10-year HHS contract valued at roughly $535 million to dispense VIGIV product to the U.S. government for supporting its smallpox awareness drive.
Amarin Rises on Priority Review for Vascepa Label Expansion http://www.zacks.com/stock/news/422062/amarin-rises-on-priority-review-for-vascepa-label-expansion?cid=CS-ZC-FT-422062 May 30, 2019 - Amarin's (AMRN) label expansion application for hypertriglyceridemia drug, Vascepa, gets priority review from the FDA.
BioMarin Announces Data on Hemophilia Candidate, Shares Fall http://www.zacks.com/stock/news/421580/biomarin-announces-data-on-hemophilia-candidate-shares-fall?cid=CS-ZC-FT-421580 May 29, 2019 - BioMarin (BMRN) announces significant reduction in annual bleed rate in phase III study evaluating gene therapy, valoctocogene roxaparvovec, in hemophilia A patients. However, investors are skeptical.
Pfizer's Eczema Candidate Meets All Goals in Phase III Study http://www.zacks.com/stock/news/414939/pfizers-eczema-candidate-meets-all-goals-in-phase-iii-study?cid=CS-ZC-FT-414939 May 16, 2019 - Pfizer's (PFE) investigational eczema treatment abrocitinib succeeds in pivotal late-stage study.
The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo http://www.zacks.com/stock/news/409269/the-zacks-analyst-blog-highlights-merck-pfizer-abbvie-sanofi-and-glaxo?cid=CS-ZC-FT-409269 May 06, 2019 - The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo
Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod http://www.zacks.com/stock/news/408311/pharma-stock-roundup-mrk-lly-pfe-report-q1-earnings-sny-abbv-drugs-get-eu-nod?cid=CS-ZC-FT-408311 May 03, 2019 - Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.
What's in the Cards for Novavax (NVAX) This Earnings Season? http://www.zacks.com/stock/news/406479/whats-in-the-cards-for-novavax-nvax-this-earnings-season?cid=CS-ZC-FT-406479 May 01, 2019 - Novavax (NVAX) is likely to provide update on the path forward for its two lead vaccine candidates.
Sanofi S.A. (SNY) CEO Olivier Brandicourt on Q1 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4257346-sanofi-s-sny-ceo-olivier-brandicourt-q1-2019-results-earnings-call-transcript?source=feed_sector_healthcare Apr 26, 2019 - Sanofi S.A. (NASDAQ:SNY) Q1 2019 Results Earnings Conference Call April 26, 2019 08:30 AM ET Company Participants George Grofik - Head of Investor Relations Olivier Brandicourt - Chief Executive Offic

Pages: 1234567...45

<Page 2>